Glucotrack to Showcase Three-Year Implantable CGM With 6.8% MARD Accuracy
GCTK•Glucotrack will present its fully implantable continuous blood glucose monitor at ADA 2026 Sessions, showcasing direct blood measurement, three-year implant longevity and no wearables. The company filed an IDE with FDA in May and published studies showing year-long enzyme stability and 6.8% MARD accuracy over 240 days.
1. Conference Presentation Overview
On June 6, Glucotrack’s Chief Scientific Officer will present the company’s fully implantable CBGM technology at the ADA 2026 Scientific Sessions Innovation Hub in New Orleans, highlighting direct blood measurement, multi-year implant longevity and elimination of wearable components.
2. Peer-Reviewed Study Results
In April, two peer-reviewed studies demonstrated year-long glucose oxidase enzyme stability and a 6.8% MARD accuracy over 240 days in an ovine model across 79 glucose tolerance tests, supporting the sensor’s long-term performance.
3. FDA IDE Submission and Next Steps
Glucotrack filed an Investigational Device Exemption application with the FDA in May, marking a key step toward initiating a U.S. clinical trial of its implantable CGM system and engaging with the diabetes community to refine study design.
